<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470261</url>
  </required_header>
  <id_info>
    <org_study_id>2011PW02</org_study_id>
    <nct_id>NCT01470261</nct_id>
  </id_info>
  <brief_title>Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects</brief_title>
  <acronym>ADDUCE</acronym>
  <official_title>Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zentralinstitut für Seelische Gesundheit Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universita degli Studi di Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vadaskert Child and Adolescent Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the ADDUCE project is to investigate any adverse effects of methylphenidate (trade&#xD;
      name ritalin) on growth, neurological system, psychiatric states and cardiovascular system&#xD;
      over a two year period in children and adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental&#xD;
      disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH,&#xD;
      trade name ritalin) is the most-commonly prescribed medication for ADHD children; it is also&#xD;
      increasingly used in ADHD adults. In 2007, the European Commission requested a referral to&#xD;
      the Committee for Medicinal Products for Human Use (CHMP) under Article 31 of Directive&#xD;
      2001/83/EC, as amended, for MPH because of safety concerns. The CHMP concluded that study of&#xD;
      the long-term effects of MPH on growth, sexual development, neurological system, psychiatric&#xD;
      states and cardiovascular system is needed. In response to the CHMP s concerns, the ADDUCE&#xD;
      (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects) research team has been&#xD;
      formed by a consortium of experts in the fields of ADHD, drug safety,&#xD;
      neuro-psychopharmacology and cardiovascular research.&#xD;
&#xD;
      The ADDUCE project aims to investigate the long-term adverse effects of MPH on growth,&#xD;
      neurological system, psychiatric states and cardiovascular system in children and adults.&#xD;
&#xD;
      Furthermore the ADDUCE team will develop research tools for the evaluation of adverse effects&#xD;
      of MPH on cognition and motivation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The height velocity standard deviation score</measure>
    <time_frame>2 years</time_frame>
    <description>Child's height velocity-mean height velocity for sex and age / Standard deviation of height velocity for sex and age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in growth</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion height &lt; 2nd centile, 0.4th centile (according to best available country specific norms)&#xD;
Weight (z-scores according to best available country specific norms)&#xD;
Proportion weight &lt; 2nd centile, 0.4th centile (according to best available country specific norms)&#xD;
BMI (z-scores according to best available country specific norms)&#xD;
Proportion BMI &lt; 2nd centile, 0.4th centile (according to best available country specific norms)&#xD;
Pubertal stage (Tanner stage)&#xD;
Bone age (selected sample from Italian cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to the cardiovascular system</measure>
    <time_frame>2 years</time_frame>
    <description>Heart rate&#xD;
Proportion heart rate &gt; 120 bpm&#xD;
Diastolic blood pressure&#xD;
Proportion diastolic blood pressure &gt; 90 mm/hg&#xD;
Systolic blood pressure&#xD;
Proportion systolic blood pressure &gt; 95th centile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Psychiatric state</measure>
    <time_frame>2 years</time_frame>
    <description>SNAP-IV mean scores&#xD;
Clinical Global Impressions score(CGI; severity, improvement)&#xD;
Children's Global Assessment Scale score (CGAS)&#xD;
Strengths and Difficulties questionnaire (SDQ)&#xD;
Mood and Feelings Scale (parent and child ratings)&#xD;
Developmental and Wellbeing Assessment&#xD;
DAWBA Rapidly changing mood section (proportion &gt; cut off)&#xD;
DAWBA tics section (proportion &gt; cut off)&#xD;
Columbia - Suicide Severity Rating Scale&#xD;
Psychosis-like symptoms&#xD;
Substance Use Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological state</measure>
    <time_frame>2 years</time_frame>
    <description>Child's Sleep Habits Questionnaire (CSHQ; total score and subscale scores, proportion &gt; cut offs)&#xD;
Abnormal Involuntary Movement Scale (AIMS; total score, Q8 score)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1398</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>ADHD medicated</arm_group_label>
    <description>Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD unmedicated controls</arm_group_label>
    <description>Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ADHD controls</arm_group_label>
    <description>Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (&lt;1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Attention Deficit Disorder clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ADHD-treated group:&#xD;
&#xD;
          -  Clinical diagnosis of ADHD&#xD;
&#xD;
          -  Aged between 5 and 17 years.&#xD;
&#xD;
          -  Not previously treated with methylphenidate&#xD;
&#xD;
          -  Agreement between clinician, patient and their family to commence on methylphenidate&#xD;
             (baseline measures will be taken before first prescription of methylphenidate is&#xD;
             issued).&#xD;
&#xD;
          -  Any co-medication other than dexamfetamine or atomoxetine will be allowed.&#xD;
&#xD;
          -  All psychiatric and physical illness comorbidities will be allowed&#xD;
&#xD;
        ADHD-unmedicated controls:&#xD;
&#xD;
          -  Clinical diagnosis of ADHD not previously treated with medication.&#xD;
&#xD;
          -  Aged between 5 and 17 years.&#xD;
&#xD;
          -  Agreement between clinician, patient and their family not to treat with&#xD;
             methylphenidate.&#xD;
&#xD;
          -  Any medication other than dexamfetamine or atomoxetine will be allowed.&#xD;
&#xD;
          -  All comorbidities will be allowed.&#xD;
&#xD;
        Non-ADHD controls:&#xD;
&#xD;
          -  Child who does not have ADHD.&#xD;
&#xD;
          -  Aged between 5 and 17 years.&#xD;
&#xD;
          -  Mean total clinician rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) score&#xD;
             (ADHD items) &lt; 1.5&#xD;
&#xD;
          -  Parent rated Strengths and Difficulties Questionnaire (SDQ) Hyperactivity Score within&#xD;
             normal range for country (e.g. &lt; 6 for UK)&#xD;
&#xD;
          -  Any current medication other than dexamfetamine or atomoxetine will be allowed.&#xD;
&#xD;
          -  Must never have taken methylphenidate&#xD;
&#xD;
          -  Any other mental health or physical illness diagnoses will be allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Groups:&#xD;
&#xD;
          -  Current or past treatment with dexamfetamine or atomoxetine.&#xD;
&#xD;
        Un-medicated ADHD controls:&#xD;
&#xD;
          -  Previous or current treatment with methylphenidate.&#xD;
&#xD;
        Non-ADHD controls:&#xD;
&#xD;
          -  Previous or current treatment with methylphenidate.&#xD;
&#xD;
          -  Clinician rated SNAP score ≥ 1.5. Parent rated SDQ Hyperactivity Score in Borderline&#xD;
             or Abnormal range.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Coghill, '</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralinstitut fuer seelische gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Stadtkreis</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.adhd-adduce.org/page/view/2/Home</url>
    <description>Study website</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Sarah Inglis</investigator_full_name>
    <investigator_title>Trial Manager</investigator_title>
  </responsible_party>
  <keyword>methylphenidate</keyword>
  <keyword>ritalin</keyword>
  <keyword>Attention Deficit Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

